Engflag

Flogoprofen

Quick links to important sections

Flogoprofen

Flogoprofen_L

Method of action: Analgesic, Anti-Inflammatory, Antirheumatic, Topical Products For Joint And Muscular Pain

Treatment option: Bursitis, Myositis

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Flogoprofen

Quick Facts

Property Description
Active ingredient Etofenamate
Form Cutaneous solution (Spray) or Gel
Pharmacological class Non-steroidal Anti-inflammatory Drug (NSAID)
Common use Relief of localized pain and inflammation
Origin Synthetic compound

Flogoprofen: Identity and Pharmacological Classification

Flogoprofen is a brand name for a pharmaceutical preparation whose active ingredient is Etofenamate, which is chemically classified as a Non-steroidal Anti-inflammatory Drug (NSAID). Etofenamate is a synthetic compound and an anthranilic acid derivative formulated specifically for external, topical use. This substance belongs to a broad pharmacological class recognized for its ability to reduce inflammation and pain, acting as both an anti-inflammatory and an analgesic agent. Flogoprofen is recognized for symptomatic relief as an Over-the-Counter (OTC) medicine.

The Form and Type of Etofenamate for Local Action

The medicinal entity Flogoprofen is strictly designed for the topical route of administration, distinguishing it from systemically acting medications. It is typically available as a cutaneous solution (spray) or a gel formulation, utilizing a vehicle to facilitate efficient dermal penetration and transport of the active ingredient. Etofenamate's primary application is for the symptomatic treatment of pain in the soft tissues. As a single-active-ingredient product, its formulation is intended for focused application, particularly for adults and adolescents, where it provides a local therapeutic effect.

General Purpose: Relief Through Anti-inflammatory Mechanism

The general purpose of Flogoprofen is to provide effective symptomatic relief by targeting both the pain and inflammation in localized soft tissues. Etofenamate achieves this by inhibiting the activity of cyclooxygenase enzymes, which are responsible for the biosynthesis of prostaglandins—the chemical mediators that signal pain and drive the inflammatory process. This mechanism of localized prostaglandin modulation delivers a targeted effect. By modulating these pro-inflammatory chemicals, the drug exerts both a peripheral analgesic effect and a local anti-inflammatory effect, offering a focused approach to managing discomfort associated with musculoskeletal disorders.

Regulatory References

  1. European Medicines Agency (EMA)
  2. EMA Etofenamate Review

What side effects are possible with Flogoprofen?

Possible side effects and safety information

The official regulatory safety profile for topical Etofenamate is based primarily on Skin and Subcutaneous Tissue Disorders due to its cutaneous route of administration. The documented adverse reactions are categorized by frequency as defined in official government sources.

Frequency-Classified Adverse Reactions

Classification Examples of Documented Adverse Reactions
Rare Contact dermatitis at the application site.
Very Rare Urticaria, bullous reactions, including Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN).
Not Known Local irritation phenomena, such as erythema (redness), pruritus (itching), and burning sensation.

High-Level Safety Considerations

The regulatory documentation highlights the potential, albeit very rare risk of severe cutaneous adverse reactions (SCARs), which include SJS and TEN. These serious reactions are often documented as being more likely to occur at the beginning of treatment. Due to the nature of the active ingredient, the possibility of systemic effects cannot be entirely excluded, though the risk is generally considered low.

Safety Restrictions and Populations: The product is not recommended for use in the paediatric population (children) or during pregnancy and lactation. It is officially contraindicated for use on open wounds, damaged skin, or mucous membranes. A key safety note is the mandatory avoidance of sun or UV exposure to the application area, as this carries a risk of photosensitivity.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory guidance for Etofenamate topical solution (Flogoprofen) addresses the risk of overdose in two distinct contexts, based strictly on documentation from governmental health authorities.

Overdose Presentations and Risk

Overdosage resulting from the topical application of Flogoprofen to the skin is not considered a practical possibility by regulatory authorities. Due to the route of administration, official labeling does not document a specific cluster of clinical signs or symptoms related to the misuse or overuse of the medicine on the skin.

However, the possibility of systemic effects cannot be entirely excluded, as the active substance undergoes cutaneous absorption. The potential for systemic exposure is noted to depend on factors such as the area of skin exposed, the quantity of medicine applied, and the total duration of exposure.

Required Emergency Actions

The critical overdose scenario outlined in regulatory documents is accidental ingestion (swallowing the medicine). This event triggers a specific, immediate emergency protocol.

Immediate medical help is required if Flogoprofen is accidentally swallowed. In this event, official guidance mandates two specific actions: the patient must seek medical advice immediately and immediately go to a hospital. The regulatory text specifies that adequate therapeutic measures should be implemented at the hospital, and requires the patient to take the package and the tube (medicine container) to the medical facility for documentation. The official labeling does not state the availability of a specific antidote for Etofenamate overdose.

Therapeutic Uses of Flogoprofen

What Flogoprofen Treats: Main Uses and Benefits

Therapeutic Scope

The therapeutic application of this topical Non-steroidal Anti-inflammatory Drug (NSAID) is relevant for easing symptoms related to pain and inflammation that create noticeable physiological strain at the site of discomfort. Its use for localized symptoms arising from musculoskeletal disorders is commonly applied in clinical settings, and is considered relevant across domains where additional symptomatic support is needed. The application of this medication is applied in addressing symptomatic relief in situations where patients experience localized discomfort.

The medication is generally used to help manage acute symptoms arising from common conditions such as muscle strains, mild sprains, contusions, localized bursitis, and general regional muscle pain (myalgia). It provides supportive relief when symptoms interfere with routine activities. It supports the patient during difficult episodes by easing distress and helps maintain a sense of stability when symptoms are more noticeable.

Quick Fact: Symptomatic Management for Musculoskeletal Discomfort

Symptom Category Therapeutic Benefit
Acute Pain and Swelling Assists with maintaining functional stability and general well-being during symptomatic phases.
Regional Stiffness/Tension Contributes to easing the overall symptom load during symptomatic periods (e.g., lumbago, torticollis).
Traumatic Injuries Applied when sudden symptoms create noticeable strain (e.g., minor sprains, contusions).

Eligibility and Restrictions for Use

Who Can and Cannot Use Flogoprofen?

This information reflects the official population eligibility and non-eligibility for Flogoprofen (etofenamate), as stated in regulatory prescribing information.

Contraindications (Must Not Use)

Flogoprofen is strictly contraindicated for individuals with:

  • A known allergy or hypersensitivity to the active substance, etofenamate, or any other ingredients.
  • A history of allergic reactions, such as asthma, urticaria, or acute rhinitis, triggered by aspirin or other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs).
  • Children under 12 years of age.
  • Pregnant women, especially during the third trimester.

Use Restrictions and Special Considerations

Population/Condition Regulatory Status
Pediatric Use Approved for adolescents 12 years and older.
Pregnancy/Lactation Contraindicated in pregnancy. Use during lactation requires medical advice and must avoid application to the breasts.
Skin Integrity Must not be applied to mucous membranes, eyes, or areas of injured, broken, or irritated skin (e.g., eczema, wounds).
Elderly Patients Use with special caution, as they may be more susceptible to systemic adverse effects.
Comorbidities Use with caution in patients with a history of gastrointestinal ulcers, renal impairment, or hepatic impairment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Flogoprofen (Etofenamate topical) is formulated for localized action, and official regulatory documentation reflects a profile primarily focused on site-specific administration constraints rather than systemic drug-drug interactions.

Documented Interaction Profile

Interaction Type Official Regulatory Statement
Systemic Drug-Drug Interactions None known with other medicinal products.
Metabolic/PK Interactions None documented to alter the plasma concentration or clearance of co-administered systemic drugs.
Food, Alcohol, Supplements None known.

Administration Restrictions

The most significant interaction constraints relate to the site and method of application. Regulatory information classifies co-administration with other localized treatments as a prohibited combination:

  • Contraindicated Combinations: Co-administration with other topical preparations (creams, gels, or solutions) on the same site of application is contraindicated.
  • Procedural Restrictions: The medicine must not be used with occlusive dressings or tight bandages placed over the area of application. This constraint addresses the potential for non-standard systemic absorption.

This structure ensures adherence to regulatory guidelines by focusing solely on official label statements regarding local administration prohibitions and the absence of known systemic medicinal product interactions.

Mechanism of Action

Targeting Cyclooxygenase (COX) Enzymes

Flogoprofen operates via its active component, which functions as an enzyme inhibitor targeting the Cyclooxygenase-1 ( COX-1) and Cyclooxygenase-2 ( COX-2) enzymes. This interaction interrupts the initial molecular step in the conversion of arachidonic acid.

Modulating Prostaglandin Synthesis

Inhibition of the COX enzymes prevents the excessive creation of prostaglandins, which are chemical mediators responsible for influencing afferent neural signaling and local vascular permeability. This action effectively reduces the output of the eicosanoid pathway signaling, which results in the modulation of the localized physiological response.

Localized Peripheral Action

The formulation facilitates the permeation of the active component through the cutaneous layers, leading to local concentration and enzyme inhibition in the underlying tissue. This peripheral focus ensures the core mechanistic action is localized, resulting in changes in peripheral fluid dynamics and altered afferent neural signaling at the site of administration.

Dosage and Administration Information

Official Administration Guidelines

Flogoprofen (Etofenamate topical) is administered strictly via the topical route. Adherence to label-based instructions is necessary for its proper use.

Dosage and Frequency

The product is available as a gel (50 mg/g) or a cutaneous solution (50 mg/ml).

Feature Official Instruction
Route of Administration Topical (cutaneous)
Dose Amount A small amount, or 5–10 cm strip of gel, applied to the affected area
Dosing Frequency Up to 3 or 4 times daily

Procedural Steps and Use Constraints

The product must be applied to the affected area and gently massaged into the skin until completely absorbed. Users must wash hands thoroughly after application to avoid contact with sensitive areas. The use is not recommended for children under 12 years of age; it is intended for adults and adolescents aged 12 and older.

Use Constraint Official Instruction
Skin Condition Must be applied only to intact skin
Treatment Duration Treatment should be reviewed after 14 days and should not extend beyond 6 weeks.
Dressings The use of occlusive dressings (airtight covers) over the application area is prohibited.

These official, label-based instructions define the standardized and permissible way the medicine must be administered, establishing clear parameters for its external use.

Recent Clinical Evidence

Flogoprofen is the brand name for a topical non-steroidal anti-inflammatory drug (NSAID) primarily used for the symptomatic relief of pain and inflammation in soft tissues. Its active substance is etofenamate, which functions as a prodrug that is converted to flufenamic acid in the body. As an NSAID, the medication is understood to inhibit prostaglandin synthesis, a process associated with pain, inflammation, and fever.

Clinical Applications and Study Findings

Clinical research on Flogoprofen and its active ingredient, etofenamate, has largely focused on its use as a topical treatment for localized musculoskeletal issues. The medication is typically evaluated for conditions such as:

  • Acute Traumatic Injuries: Sprains, strains, contusions, and soft tissue injuries.
  • Musculoskeletal Pain: Pain associated with joints, muscles, tendons, and ligaments.

Studies have investigated the medication’s performance against a placebo (carrier) and other topical and oral NSAIDs. Results from systematic reviews suggest that topical NSAIDs, in general, are effective for localized musculoskeletal pain when compared to topical placebo. The low systemic absorption achieved with topical application is theorized to minimize the risk of gastrointestinal adverse events commonly associated with oral NSAIDs, although local skin reactions may be observed more frequently.

Safety Profile and Considerations

Observed adverse reactions with etofenamate are typically localized and mild. The most commonly reported skin reaction is allergic contact dermatitis. Due to the presence of etofenamate, there is a risk of developing photocontact allergic dermatitis (a skin reaction when exposed to UV or sunlight). Patients using the topical formulation are advised to limit sun exposure on the application area to mitigate this risk. In rare cases, more severe cutaneous reactions have been documented.

How should Flogoprofen be stored and disposed of?

Flogoprofen, commonly available as a topical gel, must be stored and disposed of correctly to maintain its integrity and prevent accidental exposure.

Storage Guidelines

Flogoprofen gel should be kept at room temperature, typically between 20 C and 25 C (68 F and 77 F). It must be protected from freezing and excessive heat. Keep the container tightly closed when not in use. Always store the medication in a secure place, out of the reach and sight of children and pets, to prevent ingestion or misuse. Do not store the medication in damp areas, such as a bathroom.

Disposal Instructions

Do not dispose of expired or unused Flogoprofen gel by pouring it down a drain or flushing it down a toilet. To ensure proper disposal, consult your pharmacist or local waste disposal service about medication take-back programs. These programs are the preferred method for the safe disposal of unused medicines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagHong Kong

flagMalta

flagSpain

Equivalent of Flogoprofen found in:

A-Z Index: